

Working Group 1, proposal 1 details

1. The WHO IGWG PHI should support a treaty on R&D, that deals with priority setting and addresses the question of who pays for essential medical R&D.
2. The incentive mechanisms to stimulate R&D on new medicines should not be linked to the price of medicines, but rather, should reward the impact of inventions on health care outcomes.